Wiriyasermkul Pattama, Moriyama Satomi, Kongpracha Pornparn, Nagamori Shushi
Laboratory of Bio-Molecular Dynamics, Department of Collaborative Research, Nara Medical University.
Yakugaku Zasshi. 2021;141(4):501-510. doi: 10.1248/yakushi.20-00204-2.
Nutrients are essential for all living organisms. Because growing cancer cells have strong metabolic demands, nutrient transporters are constitutively increased to facilitate the nutrient uptake. Among these nutrient transporters, L-type amino acid transporter 1 (LAT1), which transports large neutral amino acids including essential amino acids, is critical for cancer growth. Therefore, LAT1 has been considered as an attractive target for diagnosis and therapy of cancers. We have developed several lines of compounds for cancer diagnosis and therapy. To diagnose cancer by using positron emission tomography (PET) probes, we have created amino acid derivatives which are selectively transported by LAT1 and accumulated in cancer cells. In addition to amino acid derivatives as the LAT1 inhibitors, we also have made non-amino acid small compounds as anti-cancer drugs which inhibit LAT1 function and suppress tumor growth. The LAT1 targeting anti-cancer drug showed low toxicity but strong effects on various types of cancer cells in animal models. The novel PET probe is approved for clinical research and the new anti-cancer drug has been under clinical trial. Small compounds targeting the amino acid transporter bring us new tools for cancer diagnosis and therapy.
营养物质对所有生物来说都是必不可少的。由于不断生长的癌细胞具有强烈的代谢需求,营养转运蛋白会持续增加以促进营养物质的摄取。在这些营养转运蛋白中,负责转运包括必需氨基酸在内的大型中性氨基酸的L型氨基酸转运体1(LAT1)对癌症生长至关重要。因此,LAT1被认为是癌症诊断和治疗的一个有吸引力的靶点。我们已经开发了几种用于癌症诊断和治疗的化合物系列。为了使用正电子发射断层扫描(PET)探针诊断癌症,我们制备了可被LAT1选择性转运并在癌细胞中积累的氨基酸衍生物。除了作为LAT1抑制剂的氨基酸衍生物外,我们还制备了作为抗癌药物的非氨基酸小分子化合物,它们可抑制LAT1功能并抑制肿瘤生长。在动物模型中,靶向LAT1的抗癌药物显示出低毒性但对各种类型的癌细胞有强烈作用。这种新型PET探针已获批用于临床研究,新的抗癌药物正在进行临床试验。靶向氨基酸转运体的小分子化合物为我们带来了癌症诊断和治疗的新工具。